A study on the safety and effects of the drug DMT in healthy smoking individuals

This double-blind placebo-controlled trial aims to assess the effects of DMT on healthy participants who smoke (n=50).

5 groups of 10 participants will be administered DMT (0.12 – 2.1 mg/kg) intravenously (IV). Participants will stay at the study centre overnight and will have a follow-up visit 7-9 days after DMT administration.

The trial is sponsored by Entheon Biomedical and aims to pave the way for further studies into the possibilities of using DMT to treat smoking addiction.

Topic Smoking
Compound DMT
Country Netherlands
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Entheon Biomedical
Entheon Biomedical is a listed (CSE) company that aims to develop DMT for addiction treatment.

Leiden University
Leiden University Medical Center is doing several studies into psychedelics. They do this in cooperation with other universities (e.g. Utrecht University) and companies (e.g. COMPASS).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.